Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2017 1
2018 1
2019 1
2020 3
2021 4
2022 1
2023 1
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

11 results

Results by year

Filters applied: . Clear all
Page 1
Quality of life and symptoms among patients with relapsed/refractory AL amyloidosis treated with ixazomib-dexamethasone versus physician's choice.
Sanchorawala V, Wechalekar AD, Kim K, Schönland SO, Landau HJ, Kwok F, Suzuki K, Dispenzieri A, Merlini G, Comenzo RL, Cherepanov D, Hayden VC, Kumar A, Labotka R, Faller DV, Kastritis E. Sanchorawala V, et al. Am J Hematol. 2023 May;98(5):720-729. doi: 10.1002/ajh.26866. Epub 2023 Feb 14. Am J Hematol. 2023. PMID: 36708469 Free article. Clinical Trial.

ASQ total score trended downward (lower burden) in both arms; significant LS mean differences favored ixazomib-dexamethasone over PC at some cycles (p < .05). Patients with relapsed/refractory AL amyloidosis treated with ixazomib-dexamethasone experienced

…
ASQ total score trended downward (lower burden) in both arms; significant LS mean differences favored ixazomib-dexamethasone over PC at some …
Progress in research: Daratumumab improves treatment outcomes of patients with AL amyloidosis.
Hassan H, Anwer F, Javaid A, Hashmi H. Hassan H, et al. Crit Rev Oncol Hematol. 2021 Sep;165:103435. doi: 10.1016/j.critrevonc.2021.103435. Epub 2021 Jul 31. Crit Rev Oncol Hematol. 2021. PMID: 34343658 Review.
Daratumumab (Dara) with or without standard chemotherapy appears to be an excellent treatment option for newly diagnosed and relapsed refractory AL amyloidosis. This is largely due to its tolerable safety and remarkable efficacy as seen in multiple retrospect …
Daratumumab (Dara) with or without standard chemotherapy appears to be an excellent treatment option for newly diagnosed and relapsed ref …
Venetoclax induces deep hematologic remissions in t(11;14) relapsed/refractory AL amyloidosis.
Premkumar VJ, Lentzsch S, Pan S, Bhutani D, Richter J, Jagannath S, Liedtke M, Jaccard A, Wechalekar AD, Comenzo R, Sanchorawala V, Royer B, Rosenzweig M, Valent J, Schönland S, Fonseca R, Wong S, Kapoor P. Premkumar VJ, et al. Blood Cancer J. 2021 Jan 11;11(1):10. doi: 10.1038/s41408-020-00397-w. Blood Cancer J. 2021. PMID: 33431806 Free PMC article.
Teclistamab in relapsed or refractory AL amyloidosis: a multinational retrospective case series.
Forgeard N, Elessa D, Carpinteiro A, Belhadj K, Minnema M, Roussel M, Huart A, Javaugue V, Pascal L, Royer B, Talbot A, Gounot R, Hegenbart U, Schonland S, Karlin L, Harel S, Kastritis E, Bridoux F, Jaccard A, Arnulf B. Forgeard N, et al. Blood. 2024 Feb 22;143(8):734-737. doi: 10.1182/blood.2023022937. Blood. 2024. PMID: 38096365 No abstract available.
Treatment with daratumumab in patients with relapsed/refractory AL amyloidosis: a multicentric retrospective study and review of the literature.
Lecumberri R, Krsnik I, Askari E, Sirvent M, González-Pérez MS, Escalante F, Pradillo V, Tamariz LE, Cánovas V, Alegre A, Gironella M, González-García ME, Infante MS, Lakhwani S, Martínez-Bilbao C, Dourdil V, Ramírez-Payer Á, Sarrá J, Cibeira MT. Lecumberri R, et al. Amyloid. 2020 Sep;27(3):163-167. doi: 10.1080/13506129.2020.1730791. Epub 2020 Feb 28. Amyloid. 2020. PMID: 32106714 Clinical Trial.
Daratumumab for relapsed AL amyloidosis-When cumulative real-world data precedes clinical trials: A multisite study and systematic literature review.
Shragai T, Gatt M, Lavie N, Vaxman I, Tadmor T, Rouvio O, Zektser M, Horowitz N, Magen H, Ballan M, Suru C, Luttwak E, Levi S, Ziv-Baran T, Avivi I, Cohen YC. Shragai T, et al. Eur J Haematol. 2021 Feb;106(2):184-195. doi: 10.1111/ejh.13535. Epub 2020 Nov 9. Eur J Haematol. 2021. PMID: 33090552
OBJECTIVES: Patients with relapsed/refractory AL amyloidosis (RRAL) have poor prognosis, but emerging data shows promising results with the use daratumumab. ...
OBJECTIVES: Patients with relapsed/refractory AL amyloidosis (RRAL) have poor prognosis, but emerging data shows promis …
Pomalidomide and dexamethasone grant rapid haematologic responses in patients with relapsed and refractory AL amyloidosis: a European retrospective series of 153 patients.
Milani P, Sharpley F, Schönland SO, Basset M, Mahmood S, Nuvolone M, Kimmich C, Foli A, Sachchithanantham S, Merlini G, Wechalekar A, Palladini G, Hegenbart U. Milani P, et al. Amyloid. 2020 Dec;27(4):231-236. doi: 10.1080/13506129.2020.1767566. Epub 2020 May 25. Amyloid. 2020. PMID: 32449385
A phase 1/2 study of the oral proteasome inhibitor ixazomib in relapsed or refractory AL amyloidosis.
Sanchorawala V, Palladini G, Kukreti V, Zonder JA, Cohen AD, Seldin DC, Dispenzieri A, Jaccard A, Schönland SO, Berg D, Yang H, Gupta N, Hui AM, Comenzo RL, Merlini G. Sanchorawala V, et al. Blood. 2017 Aug 3;130(5):597-605. doi: 10.1182/blood-2017-03-771220. Epub 2017 May 26. Blood. 2017. PMID: 28550039 Free PMC article. Clinical Trial.
Ixazomib was administered to adult patients with relapsed/refractory AL amyloidosis after 1 or more prior lines of therapy (including bortezomib) on days 1, 8, and 15 of 28-day cycles, for up to 12 cycles. ...Weekly oral ixazomib appears to be active in patie …
Ixazomib was administered to adult patients with relapsed/refractory AL amyloidosis after 1 or more prior lines of ther …
A randomized phase 3 study of ixazomib-dexamethasone versus physician's choice in relapsed or refractory AL amyloidosis.
Dispenzieri A, Kastritis E, Wechalekar AD, Schönland SO, Kim K, Sanchorawala V, Landau HJ, Kwok F, Suzuki K, Comenzo RL, Berg D, Liu G, Kumar A, Faller DV, Merlini G. Dispenzieri A, et al. Leukemia. 2022 Jan;36(1):225-235. doi: 10.1038/s41375-021-01317-y. Epub 2021 Jun 24. Leukemia. 2022. PMID: 34168284 Free PMC article. Clinical Trial.
In the first phase 3 study in relapsed/refractory AL amyloidosis (TOURMALINE-AL1 NCT01659658), 168 patients with relapsed/refractory AL amyloidosis after 1-2 prior lines were randomized to ixazomib (4 mg, days 1, 8, 15) plus dexamethasone …
In the first phase 3 study in relapsed/refractory AL amyloidosis (TOURMALINE-AL1 NCT01659658), 168 patients with relaps …
Efficacy of lenalidomide as salvage therapy for patients with AL amyloidosis.
Kastritis E, Gavriatopoulou M, Roussou M, Bagratuni T, Migkou M, Fotiou D, Ziogas DC, Kanellias N, Eleutherakis-Papaiakovou E, Dialoupi I, Ntanasis-Stathopoulos I, Spyropoulou-Vlachou M, Psimenou E, Gakiopoulou H, Marinaki S, Papadopoulou E, Ntalianis A, Terpos E, Dimopoulos MA. Kastritis E, et al. Amyloid. 2018 Dec;25(4):234-241. doi: 10.1080/13506129.2018.1540410. Epub 2019 Jan 20. Amyloid. 2018. PMID: 30663408
We retrospectively evaluated 55 consecutive patients who received at least one dose of lenalidomide for relapsed/refractory AL amyloidosis. Their median age was 63 years; 72% had heart and 75% kidney involvement and 13% were on dialysis; while 20%, 46% and 34 …
We retrospectively evaluated 55 consecutive patients who received at least one dose of lenalidomide for relapsed/refractory AL …
11 results